The outlier: 2020 may go down as one of the biggest economic meltdowns in US history — but biopharma is booming
Over the first half of the year, we saw scores of drug trials roiled by the pandemic, with early stage studies derailing as sites shuttered and patients hunkered down. Public biopharma companies saw some of that turmoil reflected in their earnings, particularly now that the Q2 numbers are coming in.
So maybe this isn’t such a great sector to invest in right now?
The sophisticated money says that’s absolutely wrong.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,800+ biopharma pros reading Endpoints daily — and it's free.